Treatments that target NLRP3 activity, including MCC950, have decreased TBI's IL-1β and caspase-1 activity and boosted Aβ phagocytosis in AD, as well as NLRP3 and microglia activation. This evidence concerns the gene IL1B and Alzheimer disease.